Use of Oral Hypoglycemic Agents in Type 2 Diabetic Patients with Hepatic Dysfunction.
10.4093/jkd.2011.12.4.190
- Author:
Ki Young LEE
1
Author Information
1. Devision of Endocrinology and Metabolism, Department of Internal Medicine, Gachon University School of Medicine, Incheon, Korea. ylee@gilhospital.com
- Publication Type:Original Article
- Keywords:
Type 2 diabetes mellitus;
Liver diseases;
Hypoglycemic agents;
Oral administration
- MeSH:
Administration, Oral;
alpha-Glucosidases;
Biguanides;
Diabetes Mellitus, Type 2;
Heart Failure;
Hepatitis B;
Humans;
Hypoglycemic Agents;
Korea;
Liver Diseases;
Liver Diseases, Alcoholic;
Prevalence;
Protease Inhibitors;
Thiazolidinediones
- From:Journal of Korean Diabetes
2011;12(4):190-193
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The prevalence of type 2 diabetes mellitus in the Korea has increased dramatically over the past decade. Clinicians can prescribe the following six currently available classes of oral hypoglycemic agents: sulfonylureas, meglitinides, biguanides, thiazolidinediones, alpha-glucosidase inhibitors and dipeptidyl peptidase inhibitors. The availability of various oral hypoglycemic agents has given rise to several adverse effects and may result in worse outcomes in patients with comorbid conditions such as liver dysfunction, renal impairment and heart failure. When taking a cross-sectional view of hepatic dysfunction, we find that hepatitis B and alcoholic liver disease are most prevalent in Korea. The use of oral hypoglycemic agents in type 2 diabetic patients with hepatic dysfunction requires many considerations.
